Chemomab Therapeutics Stock
Chemomab Therapeutics Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- CEO
- Adi Mor George
- Employees
- 12
- Market cap
- $8 M
- IPO
- 12/02/2019
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of…
Chemomab Therapeutics stock: price history
1D
-1.9%
1W
-8.3%
1M
-52.3%
6M
-24.3%
YTD
-23.3%
1Y
-61.4%
2Y
-74.9%
5Y
-96.5%
10Y
–
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~2% stronger price swings than usual
Ask the agents about Chemomab Therapeutics
Analyst assessment of Chemomab Therapeutics
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 27/08/2025
Chemomab Therapeutics stock metrics
P/E
-1.24
P/B
1.17
EV/EBITDA
-0.23
RETURN ON EQUITY
-25.4%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.0%
FLOAT SHARES
5,540,621
AVG. DAILY VOLUME (30D)
115,302
Insider transactions (SEC)
Cohen Neil Harris
Cohen Neil Harris
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Chemomab Therapeutics stock
What does Chemomab Therapeutics do?
Chemomab Therapeutics Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Israel.
The CEO is Adi Mor George, the company employs around 12 people.
The IPO was on 12/02/2019; the stock trades on NASDAQ under the ticker CMMB.
What do analysts say about Chemomab Therapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 27/08/2025).
This is an external assessment, not a statement by Market Jury.
When does Chemomab Therapeutics report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 2% stronger than usual.
Does Chemomab Therapeutics pay a dividend?
No, Chemomab Therapeutics currently does not pay a dividend.
Which stocks are comparable to Chemomab Therapeutics?
Comparable stocks include Alpha Tau Medical, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Chemomab Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Chemomab Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.